GE Healthcare just received FDA clearance for and is bringing to market its new Vivid E9 Breakthrough 2012 (BT12) cardiovascular ultrasound system.
The new system includes a 4D transesophageal echocardiography (TEE) transducer, allowing for its use during invasive surgical procedures, as well as minimally invasive procedures in the cath lab.
The Vivid E9 BT12 also includes several features that are new to cardiovascular ultrasound, designed to enhance 4D imaging and workflow. These include the industry’s first configurable TEE transducer, a new tilt and rotate function, and a live “2-Click Crop” tool. Workflow enhancements can also be achieved during mitral valve acquisition with a dedicated MV button and during quantification with a new plug-in tool that has the potential to decrease assessment time.
“The new 4D transesophageal probe developed by GE Healthcare is an advanced diagnostic tool,” said Dr. Luigi P. Badano of the University of Padua, Padua, Italy. “It combines ease of use and flexibility to acquire 4D data sets, user-friendly navigation tools that allow users to quickly visualize the cardiac structure of interest, and effective quantification software to quantitate left ventricular pump function, myocardial deformation and mitral valve morphology.”